login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Genous stent is a safe and effective option in STEMI patients


Friday, 09 Mar 2012 09:26
Genous
Genous

OrbusNeich has reported clinical data showing that the Genous stent is safe and effective for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Published in Revista Española de Cardiología, the data from the GENIA study show low rates of stent thrombosis and target lesion revascularisation at a mean follow-up of 538 ± 334.72 days.


In the prospective observational study, which included 139 consecutive patients undergoing primary angioplasty with implantation of one or more Genous stents, the target lesion revascularisation rate was 3.8% and the rate of definite stent thrombosis was 1.4%. In addition, the rate of cardiac death was 2.9% (four patients), and the target vessel revascularisation was 5.8%.


“STEMI is a highly prothrombotic clinical situation for which the choice of the most appropriate stent remains controversial,” said Melisa Santas-Alvarez, Departamento de Cardiología Intervencionista, Hospital Clínico de Santiago de Compostela, Spain, and first author of the study. “In high-risk situations like STEMI, drug eluting stents can delay healing of the vessel and have been associated with increased risk of thrombosis. We believe that the Genous stent’s ability to accelerate endothelialisation may reduce the risk of stent thrombosis. These results add to the growing body of knowledge confirming the safety and efficacy of Genous in STEMI patients.”


In the GENIA study, the average patient age was 64 ± 13.5 years, and 74.8% of patients were male. Notably, 20.1% of patients had multivessel disease. Patients were prescribed a regimen of antithrombotic and anticoagulant therapy in accordance with the European guidelines for the management of acute myocardial infarction.





Add New Comment

Related Items


Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

French hospital celebrates 30 years of implanting artificial hearts
Wednesday, 13 Apr 2016
La Pitié-Salpêtrière Hospital (Paris, France), the world’s leading artificial heart centre, is celebrating the 30th anniversary of the first Total Artificial Heart implantation. The centre has now ... French hospital celebrates 30 years of implanting artificial hearts

Tuesday, 05 Apr 2016
One-month, follow-up patient cohort data from the Revelution trial of Medtronic’s novel drug-filled stent indicate that device is associated with rapid vessel healing without inflammation, as ... Early data show good rapid healing for Medtronic’s investigational drug-filled stent

Features


Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy
Monday, 09 May 2016
According to Usman Baber, TWILIGHT is a unique and innovative study in that the experimental intervention is to withdraw rather than add to existing background pharmacotherapy. In this commentary, he ... Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy

The role of sutureless and rapid-deployment valves
Tuesday, 05 Apr 2016
Antonio Miceli explores the data for sutureless and rapid-deployment surgical valves for the management of patients with severe aortic stenosis. He also reviews the place of these new devices ... The role of sutureless and rapid-deployment valves

Profiles


Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions